

Hospira – Recall of buprenorphine injection and labetalol injection

- On May 21, 2024, <u>Hospira announced</u> a voluntary user-level recall of two lots of <u>buprenorphine</u> injection and three lots of <u>labetalol</u> injection due to the potential for incomplete crimp seals; one customer complaint has been received for one leaking unit.
- The recalled products were distributed nationwide to wholesalers/hospitals from September 2023 through April 2024.

Product Description	NDC number	Lot number (Exp Date)
Buprenorphine hydrochloride injection Carpuject TM single-dose cartridge/tube unit with luer lock	Carton: 0409-2012-32 Cartridge: 0409-2012-03	HJ3965 (9/2024); HJ8546 (10/2024)
Labetalol hydrochloride injection, Carpuject™ single-dose	Bundle: 0409-2339-34 Carton/cartridge: 0409-	HJ7566 (5/2025); HN8747 (9/2025);
cartridge/tube unit with luer lock	2339-24	HN8749 (9/2025)

- Buprenorphine injection is indicated for the management of pain requiring an opioid analgesic and for which alternate treatments are inadequate.
- Labetalol injection is indicated for control of blood pressure in severe hypertension.
- Anyone with an existing inventory of the product being recalled should discontinue use, stop distribution, and quarantine any of the recalled lots immediately.
- Contact Sedgwick (appointed company for Hospira) by phone at 1-800-805-3093 for questions regarding this recall.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.